Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC202314
- Development stage
- Phase 3
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWC202314 is a new molecular entity under development by Daewoong Pharmaceutical for the treatment of essential hypertension. It is classified as an antihypertensive agent, though its precise mechanism of action has not been publicly defined. The drug is being evaluated both as monotherapy and in combination with other antihypertensive agents (notably DWC202404 and DWC202405) in multiple phase III clinical trials targeting patients with essential hypertension who are inadequately controlled on monotherapy. Clinical development is ongoing primarily in South Korea, with studies focusing on oral administration in adult populations[3][5][6].
- Other names
- DWC202314DWC-202314DWC 202314
Beyond the preview
Go deeper on DWC202314.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWC202314.